← Research library

Thymopoietin pentapeptide and its synthesis — US4190646A

Patent disclosure · 1980

What the patent describes
Solid-phase synthesis of peptides bearing the RKDVY sequence, followed by in vitro lymphocyte differentiation assays.
Reported evidence
The original patent reports differentiation of T-cell precursors in a cell assay.

Cell differentiation assay · The grant reports induction of Thy-1-positive T cells in a 1 ng/mL to 10 µg/mL concentration range for the disclosed peptide class. The synthetic peptides did not induce complement-receptor-positive B-cell differentiation.

Reported patent results

Findings described in words

The original patent reports differentiation of T-cell precursors in a cell assay.

Solid-phase synthesis of peptides bearing the RKDVY sequence, followed by in vitro lymphocyte differentiation assays.

Population or model Solid-phase synthesis of peptides bearing the RKDVY sequence, followed by in vitro lymphocyte differentiation assays.

Results · Original US grant, description and synthesis examples.
MeasureResultComparison, timing and statistics
Cell differentiation assayThe grant reports induction of Thy-1-positive T cells in a 1 ng/mL to 10 µg/mL concentration range for the disclosed peptide class. The synthetic peptides did not induce complement-receptor-positive B-cell differentiation.

The reported concentration range describes laboratory activity across the disclosed peptides. The filing provides no patient outcome data.

Source for these results ↗ · Reviewed 2026-11-14

Patent claims and provenance

Molecule. Claims cover the Arg–Lys–Asp–Val–Tyr core, certain terminal substitutions, and compositions and processes using those peptides.

The cell assays describe the same early research program as the 1979 Science paper. They do not establish a separate clinical cohort.

Publication
US4190646A ↗ · 1980-02-26
Earliest priority / filing
1975-11-11 / 1979-01-26
Original applicant / assignee
Memorial Sloan Kettering Cancer Center
Indexed status
Expired - Lifetime · checked 2026-11-14
Patent family
26676220 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Polypeptide compositions and methods

Inventors: Gideon Goldstein; David H. Schlesinger.

US4190646A

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • The cell assays describe the same early research program as the 1979 Science paper. They do not establish a separate clinical cohort.
  • The reported concentration range describes laboratory activity across the disclosed peptides. The filing provides no patient outcome data.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Related publications may describe some of the same participants or experiments.

Source details

Patent publication · Original patent text and indexed metadata

Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.

Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Sources checked

Citation

Published

Patent / reported experimentsFull text available

Gideon Goldstein, David H. Schlesinger. Thymopoietin pentapeptide and its synthesis — US4190646A US4190646A · patent family 26676220

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards